Molnupiravir
Molnupiravir
Molnupiravir (pronounced as mohl-noo-PEER-uh-veer) is an antiviral medication developed for the treatment of COVID-19. It is also known by its developmental code names MK-4482 and EIDD-2801.
Etymology
The name "Molnupiravir" is derived from the Latin words "molu", meaning "grind", and "piravir", meaning "antiviral". The name signifies the drug's function as an antiviral agent that grinds down the virus.
Mechanism of Action
Molnupiravir works by introducing errors into the RNA of the SARS-CoV-2 virus during replication. This leads to a significant decrease in the virus's ability to replicate and infect other cells.
Development and Use
Molnupiravir was developed by the biopharmaceutical companies Merck & Co. and Ridgeback Biotherapeutics. It was initially investigated for the treatment of Influenza but was later repurposed for the treatment of COVID-19.
Side Effects
Common side effects of Molnupiravir include nausea, diarrhea, and headache. Severe side effects are rare but can include allergic reactions and changes in liver function.
Related Terms
External links
- Medical encyclopedia article on Molnupiravir
- Wikipedia's article - Molnupiravir
This MedicineGPT article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski